# Xencor Inc: overview

XNCR · Nasdaq · CIK 1326732 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xncr.md) · [Financials](/companies/xncr/financials.md) · [Filings](/companies/xncr/filings.md) · [Insiders](/companies/xncr/insiders.md)

Latest reported revenue: [$51.2m](/filings/0001326732-26-000056.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001326732-26-000056).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [17.8](/filings/0001326732-25-000087.md) | [52.8 d](/filings/0001326732-26-000015.md) | [32.7](/filings/0001326732-26-000043.md) | [43.6](/filings/0001326732-26-000056.md) | [21.0](/filings/0001326732-25-000087.md) | [28.2 d](/filings/0001326732-26-000015.md) | [4.5](/filings/0001326732-26-000043.md) | [51.2](/filings/0001326732-26-000056.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(310.2%)](/filings/0001326732-25-000087.md) | [(25.0%) d](/filings/0001326732-26-000015.md) | [(131.9%)](/filings/0001326732-26-000043.md) | [(76.1%)](/filings/0001326732-26-000056.md) | [(226.3%)](/filings/0001326732-25-000087.md) | [(189.9%) d](/filings/0001326732-26-000015.md) | [(1724.1%)](/filings/0001326732-26-000043.md) | [(72.4%)](/filings/0001326732-26-000056.md) |
| Net margin | % | [(260.1%)](/filings/0001326732-25-000087.md) | [(86.3%) d](/filings/0001326732-26-000015.md) | [(147.9%)](/filings/0001326732-26-000043.md) | [(70.7%)](/filings/0001326732-26-000056.md) | [(28.7%)](/filings/0001326732-25-000087.md) | [(23.6%) d](/filings/0001326732-26-000015.md) | [(2854.7%)](/filings/0001326732-26-000043.md) | [(42.4%)](/filings/0001326732-26-000056.md) |
| Diluted EPS | $ per share | [(0.72)](/filings/0001326732-25-000087.md) | not reported | [(0.66)](/filings/0001326732-26-000043.md) | [(0.41)](/filings/0001326732-26-000056.md) | [(0.08)](/filings/0001326732-25-000087.md) | not reported | [(1.71)](/filings/0001326732-26-000043.md) | [(0.29)](/filings/0001326732-26-000056.md) |
| Free cash flow | $m | [(29.4) d](/filings/0001326732-25-000087.md) | [(51.5) d](/filings/0001326732-26-000015.md) | [(17.7)](/filings/0001326732-26-000043.md) | [(36.8) d](/filings/0001326732-26-000056.md) | [(31.0) d](/filings/0001326732-25-000087.md) | [(52.9) d](/filings/0001326732-26-000015.md) | [(68.2)](/filings/0001326732-26-000043.md) | [(56.2) d](/filings/0001326732-26-000056.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [275](/filings/0001326732-25-000015.md) | [165](/filings/0001326732-25-000029.md) | [175](/filings/0001326732-26-000015.md) | [110](/filings/0001326732-26-000015.md) | [126](/filings/0001326732-26-000015.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [15.9%](/filings/0001326732-25-000015.md) | [(50.1%)](/filings/0001326732-25-000029.md) | [(75.8%)](/filings/0001326732-26-000015.md) | [(161.5%)](/filings/0001326732-26-000015.md) | [(141.4%)](/filings/0001326732-26-000015.md) |
| Net margin | % | [30.0%](/filings/0001326732-25-000015.md) | [(33.5%)](/filings/0001326732-25-000029.md) | [(76.2%)](/filings/0001326732-26-000015.md) | [(210.5%)](/filings/0001326732-26-000015.md) | [(73.2%)](/filings/0001326732-26-000015.md) |
| Diluted EPS | $ per share | [1.37](/filings/0001326732-25-000015.md) | [(0.93)](/filings/0001326732-25-000029.md) | [(2.20)](/filings/0001326732-26-000015.md) | [(3.58)](/filings/0001326732-26-000015.md) | [(1.24)](/filings/0001326732-26-000015.md) |
| Free cash flow | $m | [(30.2)](/filings/0001326732-25-000015.md) | [(14.0)](/filings/0001326732-25-000029.md) | [(96.4)](/filings/0001326732-26-000015.md) | [(208)](/filings/0001326732-26-000015.md) | [(138)](/filings/0001326732-26-000015.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xncr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $219.8m | 13,651,261 |  | Added +615,343 |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $163.9m | 10,181,322 |  | Reduced −156,700 |
| [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $114.9m | 7,133,720 |  | Unchanged |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $109.1m | 6,777,461 |  | Unchanged |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $84.9m | 5,274,274 |  | Added +377,037 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $79.8m | 4,954,016 |  | Added +601,980 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $52.8m | 3,278,802 |  | Added +177,155 |
| [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $39.5m | 2,452,138 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $35.7m | 2,215,690 |  | Reduced −1,284,652 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $30.9m | 1,920,859 |  | Added +105,282 |

## Recent filings

[All 881 filings](/companies/xncr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-26 | 07:50 ET | [8-K](/filings/0001213900-26-112279.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-112279 |
| 2026-08-05 | 16:02 ET | [10-Q](/filings/0001326732-26-000056.md) | Quarterly report, period 2026-06-30 | 0001326732-26-000056 |
| 2026-08-05 | 16:01 ET | [8-K](/filings/0001326732-26-000055.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001326732-26-000055 |
| 2026-07-29 | 16:05 ET | [8-K](/filings/0001326732-26-000049.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001326732-26-000049 |
| 2026-06-18 | 16:43 ET | [8-K](/filings/0001326732-26-000045.md) | 5.07 Shareholder vote results | 0001326732-26-000045 |
| 2026-05-06 | 16:02 ET | [10-Q](/filings/0001326732-26-000043.md) | Quarterly report, period 2026-03-31 | 0001326732-26-000043 |
| 2026-05-06 | 16:01 ET | [8-K](/filings/0001326732-26-000042.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001326732-26-000042 |
| 2026-05-05 | 08:41 ET | [8-K](/filings/0001326732-26-000036.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001326732-26-000036 |
| 2026-04-27 | 16:02 ET | [DEF 14A](/filings/0001326732-26-000031.md) | Proxy statement, period 2026-04-27 | 0001326732-26-000031 |
| 2026-04-27 | 16:01 ET | [8-K](/filings/0001326732-26-000030.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001326732-26-000030 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001326732-26-000015.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/cb50a246-77c2-47db-84d0-948357a18cb5)

## About the filer

- CIK: 1326732
- Tickers: XNCR
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:42 ET. No prices; not investment advice.